Sentence examples for treatment class from inspiring English sources

Nonsteroidal anti-inflammatory drugs were the treatment class with the lowest adverse events withdrawals.

Ahlgren [6] also showed that before and after activator treatment, Class II patients have balanced EMG patterns.

Table 4 Mean IGF-1 level (ng/ml) with respect to orthopedic and orthodontic treatment class Group Subjects Mean IGF-1 (ng/ml) SD Median 95% confidence interval for mean p value Lower bound Upper bound Class 1 30 335 12.6 333 310 360 0.006 Class 2 15 280 10.8 285 258 302   SD, standard deviation; Class 1, orthopedic treatment class; Class 2, orthodontic treatment class.

Eligible studies must have reported MOH by treatment class (i.e. analgesic, ergot, opioid, or triptan), and according to versions of ICHD-2 [1, 7 9].

For each study we first calculated the proportion of patients with MOH in each treatment class, using the total number of patients as the denominator for both proportions.

We extend their model by including vertical transmission in both vector and host populations, and treatment class in the host population with different interaction rates.

After statistical analysis of these two treatment classes, new upper and lower bound limits of IGF-1 levels were obtained which were 310 and 360 ng/ml, respectively, for orthopedic treatment class and 258 and 302 ng/ml for orthodontic treatment class.

We extracted data on the total number of patients, the number of patients with MOH by treatment class (i.e. analgesics, ergots, opioids, and triptans), MOH diagnostic criteria, and the country/region of each study.

Table 3 Perceived efficacy and tolerance of headache prophylaxis Treatment class N Reduced frequency, n Reduced pain, n Well tolerated, n Antiserotonergics 16 5 (31.3) 3 (18.8) 7 (43.8) Tricyclic 1 None None 1 (100.0 Betaa blocker 2 1 (50.0) None 1 (50.0) Ca channel blocker 4 None None 1 (25.0) Ergot alkaloid 28 7 (25.0) 7 (25.0) 18 (64.3) Antiepileptic drug 2 None 1 (50.0) None.

Data of one subject were left out in the first cross-validation step, a PLS-DA model was built, and the treatment class membership of the subject that was left out was predicted.

The team had previously told him it would not consider placing him on the list until he completed a 60-day drug-treatment class… The Virginia-based United Network for Organ Sharing, which oversees the nation's transplant system, leaves it to individual hospitals to develop criteria for transplant candidates.